The draft guidance overturns an earlier decision made by NICE which failed to recommend the use of MabThera (rituximab) for NHS use in England and Wales to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis – an inflammation of the blood vessels. It also comes against a series of negative NICE decisions for Roche, primarily involving its cancer drug Avastin (bevacizumab), which prompted the pharma company to challenge NICE’s process to evaluate the cost-effectiveness of medicines.
Help employers find you! Check out all the jobs and post your resume.
